WEST HILLS, Calif., Oct. 8, 2025 — Thermo Fisher Scientific has introduced the Molecular Microscope® Diagnostic System for Lung (MMDx® Lung), a gene expression profiling test that improves accuracy in detecting lung transplant rejection and injury. The system uses machine learning and molecular scoring to help pathologists achieve more consistent diagnoses and guide treatment decisions.
Science Significance
The MMDx Lung test leverages AI-driven gene expression analysis from lung biopsies to quantify molecular markers of rejection, dysfunction, and injury. Using a reference library of 896 biopsy samples, the tool provides objective molecular scores that improve diagnostic reproducibility—solving a critical challenge where traditional biopsy interpretations align only 18% among pathologists.
Regulatory Significance
Developed and validated by Kashi Clinical Laboratories, MMDx Lung is a laboratory-developed test (LDT) performed in a CLIA-certified lab, ensuring compliance with U.S. diagnostic testing regulations. While not FDA-cleared as an IVD, it meets quality and validation standards required for clinical deployment under CLIA and CMS oversight. This marks a regulatory milestone in integrating AI diagnostics into transplant medicine.
Business Significance
Advertisement
The launch expands Thermo Fisher’s Transplant Diagnostics portfolio, reinforcing its market leadership in molecular pathology and precision diagnostics. Collaborating with Kashi Clinical Laboratories allows for broader U.S. adoption, complementing existing MMDx systems for kidney and heart transplants. This move positions Thermo Fisher at the forefront of AI-powered diagnostic innovation, enhancing long-term revenue streams in high-value clinical markets.
Patients’ Significance
For lung transplant recipients—who face rejection rates higher than any other solid organ group—the MMDx Lung test offers a potential breakthrough. Earlier and more precise rejection detection can help clinicians tailor immunosuppressive therapy and reduce graft loss. By improving diagnostic confidence, the tool supports better survival rates and reduced complications for thousands of patients each year.
Policy Significance
The introduction aligns with growing U.S. policy efforts to expand AI integration into clinical diagnostics while maintaining data integrity and patient safety. It supports CMS and FDA initiatives promoting digital pathology innovation, reinforcing national priorities for precision medicine and evidence-based transplant care.
Thermo Fisher’s MMDx Lung launch represents a leap forward in transplant diagnostics. By merging genomics, machine learning, and regulatory-grade lab validation, the system enhances diagnostic confidence, supports clinical decision-making, and advances the global standard for post-transplant care.
Source: Thermo Fisher Press Release
